213 related articles for article (PubMed ID: 28001152)
41. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
42. Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels.
Bruns J; Egan T; Mercier P; Zustiak SP
Acta Biomater; 2023 Jun; 163():400-414. PubMed ID: 35659918
[TBL] [Abstract][Full Text] [Related]
43. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
[TBL] [Abstract][Full Text] [Related]
44. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
45. Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming.
Chang MT; Tsai LC; Nakagawa-Goto K; Lee KH; Shyur LF
Pharmacol Res; 2022 Apr; 178():106148. PubMed ID: 35231572
[TBL] [Abstract][Full Text] [Related]
46. Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
Paulitschke V; Berger W; Paulitschke P; Hofstätter E; Knapp B; Dingelmaier-Hovorka R; Födinger D; Jäger W; Szekeres T; Meshcheryakova A; Bileck A; Pirker C; Pehamberger H; Gerner C; Kunstfeld R
Mol Cancer Ther; 2015 Mar; 14(3):757-68. PubMed ID: 25612618
[TBL] [Abstract][Full Text] [Related]
47. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.
Pucciarelli D; Lengger N; Takáčová M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Mol Med Rep; 2016 Apr; 13(4):3281-8. PubMed ID: 26936534
[TBL] [Abstract][Full Text] [Related]
48. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids.
Herrmann R; Fayad W; Schwarz S; Berndtsson M; Linder S
J Biomol Screen; 2008 Jan; 13(1):1-8. PubMed ID: 18040052
[TBL] [Abstract][Full Text] [Related]
49. Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel.
Thang ND; Nghia PT; Kumasaka MY; Yajima I; Kato M
Asian Pac J Cancer Prev; 2015; 16(2):699-705. PubMed ID: 25684511
[TBL] [Abstract][Full Text] [Related]
50. Specifically targeting ERK1 or ERK2 kills melanoma cells.
Qin J; Xin H; Nickoloff BJ
J Transl Med; 2012 Jan; 10():15. PubMed ID: 22277029
[TBL] [Abstract][Full Text] [Related]
51. Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance.
Patel D; Gao Y; Son K; Siltanen C; Neve RM; Ferrara K; Revzin A
Lab Chip; 2015 Dec; 15(24):4614-24. PubMed ID: 26542093
[TBL] [Abstract][Full Text] [Related]
52. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
53. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
54. A synthetic modular approach for modeling the role of the 3D microenvironment in tumor progression.
Singh SP; Schwartz MP; Tokuda EY; Luo Y; Rogers RE; Fujita M; Ahn NG; Anseth KS
Sci Rep; 2015 Dec; 5():17814. PubMed ID: 26638791
[TBL] [Abstract][Full Text] [Related]
55. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
[TBL] [Abstract][Full Text] [Related]
56. Everolimus selectively targets vemurafenib resistant BRAF
Ruzzolini J; Peppicelli S; Andreucci E; Bianchini F; Margheri F; Laurenzana A; Fibbi G; Pimpinelli N; Calorini L
Cancer Lett; 2017 Nov; 408():43-54. PubMed ID: 28826720
[TBL] [Abstract][Full Text] [Related]
57. Three-Dimensional Aggregated Spheroid Model of Hepatocellular Carcinoma Using a 96-Pillar/Well Plate.
Lee SY; Teng Y; Son M; Ku B; Hwang HJ; Tergaonkar V; Chow PK; Lee DW; Nam DH
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443536
[TBL] [Abstract][Full Text] [Related]
58. Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models.
Hundsberger H; Stierschneider A; Sarne V; Ripper D; Schimon J; Weitzenböck HP; Schild D; Jacobi N; Eger A; Atzler J; Klein CT; Wiesner C
Molecules; 2021 Jan; 26(3):. PubMed ID: 33573155
[TBL] [Abstract][Full Text] [Related]
59. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
60. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
